Piet Wigerinck – Fibrocor Therapeutics

March 5, 2024March 5, 2024News

Fibrocor Therapeutics enters into research and development collaboration with McQuade Center for Strategic Research and Development to advance Alport Syndrome program

Agreement includes a single digit million US$ upfront payment and additional funding that has the potential to cover the cost of studies through Phase 1b Deal is a major step forward for Fibrocor’s plans to […]

October 26, 2023October 26, 2023News

Fibrocor Therapeutics appoints William P. Newsome III as CEO and Piet Wigerinck as Chief Scientific Advisor

Seasoned biopharmaceutical executive to lead Fibrocor as it aims to reshape the future of fibrosis treatment Fibrocor is currently advancing three drug candidates for fibrotic diseases into the clinic Toronto, Canada – 25 October 2023 […]